A 14-year ACALM (The Algorithm for Comorbidities, Associations, Length of Stay and Mortality) survey of more than 1 million patients found that women with high cholesterol had a significantly lower risk of breast cancer and improved mortality. At the same time, the researchers also found that statins may reduce the morbidity and mortality of breast cancer. The results of the study were published on the same day at the ESC conference.
Dr. Rahul Potluri, founder of the ACALM research team and the University of Aston, UK, said this is the strongest evidence to confirm the link between high cholesterol diagnosis and breast cancer.
As early as 2016 at the Frontiers of Cardiovascular Biology, Dr. Paul Carter, the first author of the study and a researcher at the ACALM research team, conducted a study on controlling cholesterol levels that are expected to reduce the mortality rate of four cancers. The results showed that high cholesterol diagnosis was associated with a reduction in lung cancer, breast cancer, prostate cancer, and intestinal cancer mortality.
Dr. Paul Carter said that we have previously found a link between high cholesterol and breast cancer development. Two animal studies have confirmed that model animals with excessive cholesterol levels can effectively reduce the risk of breast cancer after taking statins. So we designed the current study to provide longitudinal follow-up of patients and more strongly confirm the link between them.
From January 1, 2000 to March 31, 2013, the researchers investigated patients with high cholesterol treatment registered in UK hospitals and recorded clinical data on their complications, survival time, high cholesterol levels, and death.
A total of 220,024 patients in the ACALM study, including 16,043 high-cholesterol patients over the age of 40, were compared with patients of similar age and no high cholesterol.
The researchers found that people with high cholesterol had a 45% lower risk of breast cancer than those without high cholesterol. After excluding factors that may affect mortality, including age, gender, ethnicity, and the top ten most common causes of death in the UK, they found that breast cancer patients with high cholesterol had a lower mortality rate than breast cancer patients without high cholesterol. %.
Dr. Potluri said that if high cholesterol diagnosis leads to a lower incidence of breast cancer, it must be related to the condition or the intrinsic things of the affected patients, or more likely to be associated with the widespread use of statins to treat high cholesterol. This is by far the strongest evidence for evaluating clinical trials in which statins have a protective effect on breast cancer patients.
Dr. Paul Carter concluded, "Breast cancer patients with high cholesterol, high risk of cardiovascular disease, and cardiovascular disease should take statins according to current guidelines. I don't think statins can be used to prevent or Reduce breast cancer mortality, but positive results from clinical trials may change this. This is an exciting and fast-growing area."
Shanghai Chuangsai Technology has excellent performance, interleukin cytokines, fetal bovine serum, electrophoresis equipment scientific instruments, raw material drug standards, chemical reagents, cell culture consumables, Shanghai Chuangsai, mass products special promotions, welcome to inquire!
Men Running shoes are very suitable for all kind of sports like running, walking, mountaineering and paly football and so on. With the top priority good quality and remorseless serivce, we are receiving more and more active feedback from our customers.Looking for ideal of Shoes Manufacturer & supplier ? We have a wide selection at goods prices to help you get creative. All the Shoes are quality guaranteed. We are China Origin Factory of Men Shoes. If you have any question, please feel free to contact us.
Running Shoes,Mesh Running Shoes,Breathable Running Shoes,Men Running Shoes
Ningbo Qizhan Trade Co.,Ltd , https://www.qizhanshoes.com